header_top_522_text header_top_522_text

The first and only 522 study to include a single incision sling and full-length retropubic and transobturator slings.

The investigators confirm that the Altis 522 24-month data, which compares Altis to FDA-cleared retropubic and transobturator slings, reflects real-world clinical practice. Thus it may provide use in counseling future patients.

 

Download Report

 

PRODUCT INFORMATION | PRIMARY EFFECTIVENESS | SECONDARY EFFECTIVENESS | SUBJECTIVE OUTCOMES | SAFETY AND EFFICACY

product_header_522_banner_desktop_updated mobile_background_altis_product_522_final

 

The single incision sling system that delivers for you and your patients.

The Altis® Single Incision Sling System is a unique, minimally invasive solution purposefully designed to provide predictable placement and adjustable control. This makes the procedure straightforward, accurate and repeatable.1

  • Patented helical introducer makes the surgical procedure straightforward, accurate and reproducible.2
  • Dynamic anchor allows for precise tensioning.2
  • Patented, lightweight mesh features low elasticity for stable support.2

 
Download Brochure

Altis Patient

Purposefully designed for a better patient experience.

The Altis® system allows for a more convenient procedure that can be performed in an outpatient setting under local anesthesia, which may lead to a faster recovery time. Patients can be back on their feet and return to work or normal activity sooner as compared to traditional full-length slings.1,2,3

 

Learn More

At 24-Months, the Altis® Single Incision Sling is Comparable to Full-Length Retropubic and Transobturator Slings

24-Month results are available for review.

Download the 24-Month Report

Patient Data
To optimally reflect real clinical practice, a nonrandomized study was performed, and the selection of the surgical intervention was based on surgeon expertise and shared decision making between the patient and physician.

The Altis® 522 study is a prospective, post-market, multicenter,
comparative cohort study performed in adult female patients with SUI who are clinically indicated for mid-urethral sling surgery.

Consistent Results

At 24 months, 24-hour pad weight success (≥50% reduction), negative CST, PGI-I, UDI-6, and IIQ-7 were similar between Altis and full-length retropubic and transobturator slings.

Altis product design (i.e., elastic properties similar to the pubourethral ligament and intraoperative adjustability post-deployment) and surgical reproducibility attributed to high objective and subjective cure rates at 24 months, comparable to full-length retropubic and transobturator slings.

The Altis 522 study was designed to have a full range of objective and subjective outcome measurements, included full-length retropubic and transobturator slings in the comparator arm, and did not exclude ISD patients.

The same rigorous and robust protocol and testing methods utilized in Altis IDE study were included in the Altis 522 study.

All commercially available full-length retropubic and transobturator slings were allowed in the comparator group.

By allowing a heterogenous group of full-length retropubic and transobturator slings in the comparator arm, and enrolling patients with a variety of characteristics, the Altis 522 study is more reflective of real world clinical practices.

The aim of the Altis 522 study is to compare the safety and effectiveness of the Altis Single Incision Sling to full-length retropubic and transobturator slings through 36 months.

Subsequent reports will follow at 36 months.

Primary Effectiveness Objective

 

Pad Weight Success

The primary efficacy objective was to demonstrate that the reduction from baseline in 24-hour pad weight associated with Altis SIS is non inferior to the rate associated with the use of transobturator and/or retropubic slings at 6 months.

At 24 months, Altis is comparable to full-length retropubic and transobturator slings.

 

*Results compared to baseline collected at 24 months.

Secondary Effectiveness Objective

 

Negative CST

Secondary efficacy measures included objective dryness(defined as pad weight ≤4.0g) and negative CST with comparative assessments between groups at 6, 12, 18, 24 and 36 months.

At 24 months, Altis is comparable to full-length retropubic and transobturator slings.

 

*Results compared to baseline collected at 24 months.

Subjective Outcomes

Subjective Outcomes Data
 

*Results compared to baseline collected at 24 months.

Subjective outcome measures collected included patient global impression of improvement (PGI-I), urogenital distress inventory (UDI-6), Incontinence Impact Questionnaire − Short Form (IIQ-7), Surgical Satisfaction Questionnaire (SSQ-8), and visual analog scale for pain (VAS). At 24 months, Altis is comparable to full-length retropubic and transobturator slings.

Safety and Efficacy Outcome Measures

 
Safety & Efficacy Graphic

No new serious procedure – and/or device-related adverse events were reported in either study arm since the previous 12-month publication.

 

References

 

ClinicalTrials.gov Identifier: NCT02348112

Altis® 522 Trial – Treatment of Female Stress Urinary Incontinence

 

  1. Mostafa A, Lim CP, Hopper L, Madhurvata P, Abdel-Fattah M. Single-incision mini-slings versus standard midurethral slings in surgical management of female stress urinary incontinence: an updated systematic review and meta-analysis of effectiveness and complications. Euro Urology. 2014;65(2):402-427. doi:10.1016/j.eururo.2013.08.032.
  2. Data on file.
  3. Erickson T. et al, A multicenter prospective Study evaluating efficacy and safety of a Single-incision sling procedure for stress urinary incontinence. JMIG2020;1-7.

ALTIS® Single Incision Sling System Brief Statement

Indications

The Altis Single Incision Sling System is indicated for the treatment of female stress urinary incontinence (SUI) resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD).

Contraindications

It is the responsibility of the physician to advise the prospective patients or their representatives, prior to surgery, of the contraindications associated with the use of this product. The Altis Single Incision Sling System is contraindicated for use in patients with the following conditions:

  • Pregnancy or desire for future pregnancy
  • Potential for further growth (e.g., adolescents)
  • Known active urinary tract infection and/or infection in operative field
  • Taking anti-coagulant therapy
  • Abnormal urethra (e.g., fistula, diverticulum)
  • Intraoperative urethral injury
  • Any condition, including known or suspected pelvic pathology, which could compromise implant or implant placement
  • Sensitivity/allergy to polypropylene

Warnings and Precautions

It is the responsibility of the physician to advise the prospective patients or their representatives, prior to surgery, of the warnings and precautions associated with the use of this product and the associated surgical risks.

Warnings

The Altis Single Incision Sling System should only be used by physicians familiar with the surgical procedures and techniques involving transvaginal placement of non-absorbable, synthetic mesh slings and who have adequate education and experience in the treatment of female SUI.

A thorough assessment of each patient should be made to determine the suitability of a synthetic mesh sling procedure.

The patient should be counseled that alternative incontinence treatments may be appropriate, and the reason for choosing a mesh sling procedure should be explained.

Obtain patient consent prior to surgery and ensure that the patient has an understanding of the postoperative risks and potential complications of transvaginal mesh sling surgery.

Patient counseling should include a discussion that the sling to be implanted is a permanent implant and that some complications associated with the implanted mesh sling may require additional surgery; repeat surgery may not resolve these complications. Serious adverse tissue responses or infection may require removal of mesh, and complete removal of the sling may not always be possible. Individuals may have varying degrees of collagen laydown that may result in scarring.

As with all surgical procedures, patients with certain underlying conditions may be more susceptible to postoperative bleeding, impaired blood supply, compromised/delayed healing, or other complications and adverse events.

The risks and benefits of using Altis should be considered in patients.

Any future pregnancy could negate the benefits of this surgical procedure. Patients should report any bleeding, pain, abnormal vaginal discharge or sign of infection that occur at any time.

The procedure to insert the Altis sling requires good knowledge of pelvic anatomy and the correct use of the introducer needles in order to avoid damage to adjacent anatomical structures.

Cystoscopy should be performed to confirm bladder and urethral integrity.

Avoid placing excessive tension on the Altis sling during placement and adjustment to maintain sling integrity and to avoid compression of the urethra when tensioning.

Potential Complications

Potential complications include mesh extrusion, pelvic/urogenital pain, groin pain, hip pain (may be related to patient positioning), urinary retention, bleeding, de novo urgency, delayed wound healing, dyspareunia, hip/groin pain, inflammation, nausea, overactive bladder, pain, pelvic hematoma, reaction to antibiotic, slight discomfort upon return to work, urinary tract infection, urine stream decreased, and voiding dysfunction.

Adverse events are known to occur with transvaginal synthetic sling procedures and implants. Adverse events following mesh implantation may be de novo, persistent, worsening, transient, or permanent.

Additional potential complications include, but are not limited to, abscess (acute or delayed), adhesion/scar formation, allergy, hypersensitivity or other immune reaction, bleeding, hemorrhage or hematoma, dehiscence, delayed wound healing, extrusion, erosion or exposure of mesh sling into the vagina or other structures or organs, fistula formation, infection, inflammation (acute or chronic), local irritation, necrosis, de novo and/or worsening dyspareunia, neuromuscular symptoms (acute or chronic), partner pain and/or discomfort during intercourse, perforation or injury of soft tissue (e.g., muscles, nerves, vessels), structures, or organs (e.g., bone, bladder, urethra, ureters, vagina), seroma, sling migration, suture erosion, bladder storage dysfunction (e.g., increased daytime frequency, urgency, nocturia, overactive bladder, urinary incontinence), ureteral obstruction, urinary tract infection, voiding symptoms (e.g., dysuria, urinary retention, incomplete emptying, straining, positional voiding, weak stream), granulation tissue formation, palpable mesh (patient and/or partner), sexual dysfunction, vaginal discharge (abnormal) and vaginal scarring or tightening.

The occurrence of these events may require one or more revision surgeries, including removal of the sling.

Complete removal of the sling may not always be possible, and additional surgeries may not always fully correct the complications.

There may be unresolved pain with or without mesh sling explanation.

The information provided is not comprehensive with regard to product risks. For a comprehensive listing of indications, contraindications, warnings, precautions, and adverse events refer to the product’s Instructions for Use. Alternatively, you may contact a Coloplast representative at 1-800-258-3476 and/or visit the company Website at www.coloplast.com.

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.